Interestingly, the reduction of AKT activation induced by the combination of COX-2 and CYP19A1 inhibitors in MPM cells represents a critical pathway in the response to treatment as detected in the onset of drug resistance in a variety of cancers [70]. This evidence concerns the gene PTGS2 and cancer.